These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1116 related articles for article (PubMed ID: 19130415)
21. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Anwaruddin S; Lloyd-Jones DM; Baggish A; Chen A; Krauser D; Tung R; Chae C; Januzzi JL J Am Coll Cardiol; 2006 Jan; 47(1):91-7. PubMed ID: 16386670 [TBL] [Abstract][Full Text] [Related]
22. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure]. Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610 [TBL] [Abstract][Full Text] [Related]
23. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Januzzi JL; Sakhuja R; O'donoghue M; Baggish AL; Anwaruddin S; Chae CU; Cameron R; Krauser DG; Tung R; Camargo CA; Lloyd-Jones DM Arch Intern Med; 2006 Feb; 166(3):315-20. PubMed ID: 16476871 [TBL] [Abstract][Full Text] [Related]
24. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism. Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527 [TBL] [Abstract][Full Text] [Related]
25. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985 [TBL] [Abstract][Full Text] [Related]
26. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease]. Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803 [TBL] [Abstract][Full Text] [Related]
27. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients. Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079 [TBL] [Abstract][Full Text] [Related]
28. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981 [TBL] [Abstract][Full Text] [Related]
29. Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. Passino C; Maria Sironi A; Favilli B; Poletti R; Prontera C; Ripoli A; Lombardi M; Emdin M Int J Cardiol; 2005 Sep; 104(1):39-45. PubMed ID: 16137508 [TBL] [Abstract][Full Text] [Related]
30. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center. Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021 [TBL] [Abstract][Full Text] [Related]
31. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Behnes M; Brueckmann M; Ahmad-Nejad P; Lang S; Wolpert C; Elmas E; Kaelsch T; Gruettner J; Weiss C; Borggrefe M; Neumaier M Int J Cardiol; 2009 Jun; 135(2):165-74. PubMed ID: 18603317 [TBL] [Abstract][Full Text] [Related]
33. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244 [TBL] [Abstract][Full Text] [Related]
34. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Bayes-Genis A; Pascual-Figal D; Fabregat J; Domingo M; Planas F; Casas T; Ordoñez-Llanos J; Valdes M; Cinca J Int J Cardiol; 2007 Sep; 120(3):338-43. PubMed ID: 17174423 [TBL] [Abstract][Full Text] [Related]
35. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. Conraads VM; Beckers P; Vaes J; Martin M; Van Hoof V; De Maeyer C; Possemiers N; Wuyts FL; Vrints CJ Eur Heart J; 2004 Oct; 25(20):1797-805. PubMed ID: 15474694 [TBL] [Abstract][Full Text] [Related]
36. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664 [TBL] [Abstract][Full Text] [Related]
37. N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluationof the Evolution of New-Heart Failure Study (SCREEN-HF). McGrady M; Reid CM; Shiel L; Wolfe R; Boffa U; Liew D; Campbell DJ; Prior D; Krum H Eur J Heart Fail; 2013 May; 15(5):573-80. PubMed ID: 23338855 [TBL] [Abstract][Full Text] [Related]
38. Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction. Palmer SC; Yandle TG; Frampton CM; Troughton RW; Nicholls MG; Richards AM Eur Heart J; 2009 Jun; 30(12):1486-94. PubMed ID: 19389787 [TBL] [Abstract][Full Text] [Related]
39. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832 [TBL] [Abstract][Full Text] [Related]
40. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. Fox PR; Oyama MA; Reynolds C; Rush JE; DeFrancesco TC; Keene BW; Atkins CE; Macdonald KA; Schober KE; Bonagura JD; Stepien RL; Kellihan HB; Nguyenba TP; Lehmkuhl LB; Lefbom BK; Moise NS; Hogan DF J Vet Cardiol; 2009 May; 11 Suppl 1():S51-61. PubMed ID: 19394287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]